Top Markets
#1 Islamic Coin Islamic Coin +151.52%
#2 Black Phoenix Black Phoenix +34.38%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.18%
#4 Akedo Akedo +12.99%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.69%
#6 clBTC clBTC +11.91%
#7 OpenEden OpenEden +10.96%
#8 Fake World Assets Fake World Assets +9.99%
#9 HOME HOME +9.85%
#10 Pons Pons +9.50%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Nabriva Therapeutics plc Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRV
Rank in Stocks #39979
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Share Price
$0.63
Last synced: 2023-08-29
Market Cap
$284.20K
Change (1 day)
-21.25%
Change (1 year)
0.00%
Country
IE
Trade Nabriva Therapeutics plc (NBRV)

Category

Healthcare
P/E ratio for Nabriva Therapeutics plc (NBRV)
P/E ratio as of 2026 TTM: 0
According to Nabriva Therapeutics plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nabriva Therapeutics plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.